[
    [
        {
            "time": "2023-10-05",
            "original_text": "Novartis Scemblix速 demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia",
            "features": {
                "keywords": [
                    "Scemblix速",
                    "sustained response",
                    "chronic myeloid leukemia",
                    "48-week follow-up"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novartis Kymriah速 demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up",
            "features": {
                "keywords": [
                    "Kymriah速",
                    "strong responses",
                    "high-risk patients",
                    "follicular lymphoma",
                    "extended study follow-up"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft",
            "features": {
                "keywords": [
                    "Sandoz",
                    "generics unit",
                    "strong interest",
                    "Finanz und Wirtschaft"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals",
                    "investing"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]